Clinical adverse events (AEs) are any unintended or harmful signs, symptoms, or conditions linked in time to the use of a medical product, regardless of causality.

Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).

GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.

Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.

The International Union of Pure and Applied Chemistry (IUPAC) is a non-governmental organization dedicated to promoting chemistry-related activities.

The European Commission has approved STADA and Alvotech's biosimilar Uzpruvo® (AVT04), similar to Stelara® (ustekinumab), for marketing.

Kymera Therapeutics began their Phase 2 ADVANTA study for KT-474 in AD on Dec 7, 2023, prompting a $15M milestone payment from Sanofi.

Verge Genomics has announced the start of its Phase 1b trial for VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS), covering both sporadic and familial forms.

The drug packaging box sent to the subject will be returned to the investigator by the subject after the end of the trial.

Corbus Pharmaceuticals Holdings, Inc., focused on precision oncology, announced FDA approval for its CRB-601 drug application.

Elpiscience Biopharma and Astellas Pharma have teamed up in a deal for the BiME® platform, advancing two drugs, ES019 and a second molecular project.

Constant Therapeutics LLC, specializing in biopharmaceuticals, announced the first patient dosed in their Phase 2 trial of TXA127, a peptide therapy aimed at improving post-stroke recovery.